Novel serotonergic and non-serotonergic migraine headache therapies

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 4, 2001, Pages 625-649

  Slassi, A ^a   Isaac, M ^a   Arora, J ^a  

^a NPS Allelix Corp   (Canada)

Author keywords

5 HT receptor subtypes; Agonists; Antagonists; Antimigraine; Non triptans; Potency; Selectivity; Side effects; Triptans

Indexed keywords

1 [2 (3 FLUOROPHENYL)ETHYL] 4 [3 [5 (1,2,4 TRIAZOL 4 YL) 1H INDOL 3 YL]PROPYL]PIPERAZINE; 1 [2 [4 (4 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N METHYLISOCHROMAN 6 CARBOXAMIDE; 2 (4 FLUOROPHENYL) 2 [1 [3 [5 (1,2,4 TRIAZOL 4 YL) 3 INDOLYL]PROPYL] 4 PIPERIDINYLAMINO]ETHANOL; 2,7 DIAZABICYLCO(3,3,0)OCTANE; 3,7 DIAZABICYLCO(3,3,0)OCTANE; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ADRENERGIC RECEPTOR STIMULATING AGENT; ALMOTRIPTAN; ANTICONVULSIVE AGENT; CYCLOOXYGENASE 2 INHIBITOR; ELETRIPTAN; FROVATRIPTAN; L 760790; LIGAND; NARATRIPTAN; NEUROPEPTIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRROLIDINE DERIVATIVE; RECEPTOR SUBTYPE; RIZATRIPTAN; SEROTONIN; SEROTONIN 1D AGONIST; SEROTONIN 1F AGONIST; SEROTONIN 5 AGONIST; SEROTONIN AGONIST; SUMATRIPTAN; TACHYKININ RECEPTOR ANTAGONIST; THROMBOXANE RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLMITRIPTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR DISEASE; CAT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MARKETING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; IC 50; MIGRAINE; NONHUMAN; PATENT; PATHOPHYSIOLOGY; RABBIT; VASOCONSTRICTION;

EID: 0035063362     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.4.625     Document Type: Article

References (72)

1. Antimigraine agents: July 1995 - December 1996
2. Naratriptan: A review
3. Zolmitriptan: A new acute treatment for migraine
4. 1D receptor agonist for the treatment of migraine
5. A triptan too far?
6. The epidemiology of migraine headache
7. Migraine prevalence. A review of population-based studies
8. Migraine heterogeneity. Disability, pain intensity and attack frequency and duration
9. Migraine symptoms: Results of a survey of self-reported migraineurs
10. The triptans: A summary
11. General principles of pharmacological treatment
12. Nonsteroidal anti-inflammatory drugs in the treatment of the acute migraine attack
13. Prevalence of migraine headache in the United States. Relation to age, income, race and other sociodemographic factors
14. Migraine pharmacotherapy with oral triptans: A rational approach to clinical management
15. Advances in migraine therapy - 5-HT receptor subtype-specific agonist drugs
16. Treatment of migraine attacks with sumatriptan
17. Clinical and experimental effects of sumatriptan in humans
18. 1D receptor agonists in the acute treatment of migraine
19. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache
20. Imitrex (sumatriptan) tablets. Physicians desk reference
21. Sumatriptan in clinical practice: A two year review of 453 migraine patients
22. Migraine
23. Headache recurrence after subcutaneous sumatriptan
24. Migraine: Current drug discovery trends
25. Neurogenic inflammation in the pathophysiology and treatment of migraine
26. Neurovascular and molecular mechanisms in migraine headaches
27. 5-HT and GABA receptors in migraine
28. 5-Hydroxytryptamine receptor subtypes and migraine
29. Selective 5-HT1Dα serotonin receptor gene expression in trigeminal ganglia: Implication for antimigraine drug development
30. 1Dbeta' receptors
31. 1F) receptor subtype: A rational target for migraine drug discovery
32. International union of pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin)
33. A review of central 5-HT receptors and their function
34. Biochemical investigations in headache: Increase in the hydroxyindoleacetic acid excretion during migraine attacks
35. Effect of serotonin in migraine patients
36. A rational approach to identifying a fundamentally new drug for the treatment of migraine
37. 1D receptor: A progress review
38. Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brain
39. 1D autoreceptors in human cerebral cortex
40. 1 erceptor agonists as antimigraine agents
41. 1D receptor agonists in migraine
42. Rizatriptan has central antinociceptive effects against durally evoked responses
43. 1B subtype
44. 1B subtype
45. 1D receptor agonists
46. 1D receptor agonists: Fluorinated 3-[3-(piperidin-1-yl)propyl] indoles
47. 1D receptor agonists
48. 1D agonists for the treatment of migraine
49. 1D receptor agonists
50. 1B/1D receptor agonists: Potential treatments for migraine
51. 1B/1D receptor agonists: Potential treatment for migraine
52. 1D agonist with reduced cardiovascular risk
53. 1B/1D receptor agonists for the acute treatment of migraine
54. 1B/1D receptors in models relevant to migraine
55. 1D agonists: Potential new treatment for migraine without cardiovascular side effects
56. 1D receptor agonist PNU-142633
57. 1B/1D serotonin receptor ligands: A structure-affinity investigation
58. Molecular biology of 5-HT receptors
59. Prospects for improved antidepressants
60. Current advances and trends in the treatment of depression
61. Neuropharmacology of anxiety: Perspectives and prospects
62. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin)
63. 1F receptor messenger RNA in rodent and primate brain
64. 1F receptor
65. 1F receptor agonist, in the neurogenic dural inflammation model of migraine pain
66. Identification of (-)-cis-6-acetyl-4S-(3-chloro-4-fluoro-benzoylamino)-3, 4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3S- as a potential antimigraine agent
67. SB-220453, A novel antimigraine agent, inhibits cortical spreading depression in the anaesthetised cat
68. 2+ channel gene CACNL1A4
69. Familial typical migraine: Linkage to chromosome 19p13 and evidence for genetic heterogeneity
70. Familial typical migraine: Significant linkage and localization of a gene to Xq24-28
71. Management of migraine: An algorithmic approach